Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP145425.RAQUiH_m6E_hGDbr3SpsC60DxLFQ8baG09jpr51z3U6MI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP145425.RAQUiH_m6E_hGDbr3SpsC60DxLFQ8baG09jpr51z3U6MI130_assertion type Assertion NP145425.RAQUiH_m6E_hGDbr3SpsC60DxLFQ8baG09jpr51z3U6MI130_head.
- NP145425.RAQUiH_m6E_hGDbr3SpsC60DxLFQ8baG09jpr51z3U6MI130_assertion description "[We analyzed the PIK3CA and KRAS mutation status in a large group (n = 200) of chemorefractory metastatic colorectal cancers treated with cetuximab (Erbitux) in monotherapy or in combination with irinotecan, and correlated the mutation status with outcome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP145425.RAQUiH_m6E_hGDbr3SpsC60DxLFQ8baG09jpr51z3U6MI130_provenance.
- NP145425.RAQUiH_m6E_hGDbr3SpsC60DxLFQ8baG09jpr51z3U6MI130_assertion evidence source_evidence_literature NP145425.RAQUiH_m6E_hGDbr3SpsC60DxLFQ8baG09jpr51z3U6MI130_provenance.
- NP145425.RAQUiH_m6E_hGDbr3SpsC60DxLFQ8baG09jpr51z3U6MI130_assertion SIO_000772 19366826 NP145425.RAQUiH_m6E_hGDbr3SpsC60DxLFQ8baG09jpr51z3U6MI130_provenance.
- NP145425.RAQUiH_m6E_hGDbr3SpsC60DxLFQ8baG09jpr51z3U6MI130_assertion wasDerivedFrom gad-20150221 NP145425.RAQUiH_m6E_hGDbr3SpsC60DxLFQ8baG09jpr51z3U6MI130_provenance.
- NP145425.RAQUiH_m6E_hGDbr3SpsC60DxLFQ8baG09jpr51z3U6MI130_assertion wasGeneratedBy ECO_0000203 NP145425.RAQUiH_m6E_hGDbr3SpsC60DxLFQ8baG09jpr51z3U6MI130_provenance.